---
title: "VK2735 in Chronic weight management: Conclusions"
description: "Formulary evidence on VK2735 in Chronic weight management: Conclusions. 1 evidence topic quoted from 15 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary/conclusions"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: Conclusions

<a id="heading-1.1.4"></a>

## 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

### Summary

VK2735 is an investigational dual GLP-1 and GIP receptor agonist developed by Viking Therapeutics as a once-weekly subcutaneous injection and a once-daily oral tablet for chronic weight management. Neither formulation is approved, and no new drug application has been submitted. The company expects data from the subcutaneous phase 3 VANQUISH trials in the second half of 2027 and from the oral phase 3 SUNRISE trials in 2028, and has given no price.

Obesity affected 40.3% of U.S. adults in 2021 to 2023, and was associated with $1,861 in excess annual medical costs per adult in 2019 dollars. Approved incretin-based comparators for chronic weight management include semaglutide (injection and tablet), tirzepatide (injection), and orforglipron (tablet).

The evidence for the subcutaneous formulation comprises one peer-reviewed phase 2 trial (VENTURE, 176 participants, 13 weeks), in which placebo-adjusted weight change at week 13 ranged from −7.43 to −13.08 percentage points across doses of 2.5 to 15 mg, and phase 1 studies reported in press releases and posters, including a maintenance study of every-other-week and monthly dosing after 21 weeks of weekly induction. The evidence for the oral formulation comprises one phase 2 trial (VENTURE-Oral Dosing, 280 participants, 13 weeks) reported in a press release, a congress poster, and company presentations, with placebo-adjusted weight change of −1.0% to −10.9% at doses of 15 to 120 mg, treatment discontinuation of 20% to 38% across dose arms compared with 18% for placebo, and a 28-day phase 1 study. In both formulations, gastrointestinal adverse events were the most common adverse events and the most common reason for discontinuing treatment.

The phase 2 trials lasted 13 weeks, excluded people with diabetes, and reported no weight-loss plateau at week 13, so the effect after the 1 year of treatment that FDA draft guidance uses as its efficacy benchmark is not known for either formulation. The oral phase 3 doses (27.5, 35, and 55 mg) were not studied as fixed-dose arms in phase 2. Efficacy and safety at the phase 3 doses and durations, in people with type 2 diabetes, and against an active comparator have not been reported for either formulation.

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update); [Viking Therapeutics Form 10-Q third quarter (2026)](https://www.sec.gov/Archives/edgar/data/1607678/000119312526436432/vktx-20260930.htm); [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf); [Emmerich et al. (2024)](https://www.cdc.gov/nchs/products/databriefs/db508.htm); [Ward et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7990296/); [Novo Nordisk Wegovy prescribing information (2026)](https://www.novo-pi.com/wegovy.pdf); [Eli Lilly Zepbound prescribing information (2026)](https://uspl.lilly.com/zepbound/zepbound.html); [Eli Lilly Foundayo prescribing information (2026)](https://uspl.lilly.com/foundayo/foundayo.html); [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/); [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens); [Viking Therapeutics VENTURE topline release (2024)](https://ir.vikingtherapeutics.com/2024-02-27-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Patients-with-Obesity); [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity); [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf); [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity); [FDA weight reduction draft guidance (2025)](https://www.fda.gov/media/71252/download)

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
